Sai Parenterals IPO

Sai Parenteral’s Limited IPO Strengths

Robust Diversification and Revenue Trajectory

Sai Parenteral’s Limited has transformed from a parenteral-focused manufacturer (2001) into a highly diversified generic formulations player offering injectables, tablets, capsules, and more across various therapeutic segments. Driven by operational efficiency and strategic expansion, the Company’s revenue surged from ₹8.6 million (2016) to ₹1,631.05 million in Fiscal 2025, demonstrating an established track record of strong financial growth and market reach.

Strategic Focus on CDMO and Exports

The Company strategically expanded its presence in Regulated and Semi-Regulated Markets by leveraging accredited facilities (Unit III and IV) to grow its exports of Branded Generic Formulations and CDMO products. This focus on long-term CDMO engagements with multinational companies diversifies the revenue mix, significantly reduces segment-specific risks, and adds essential stability and long-term visibility to its future revenue streams.

Accredited and Optimized Manufacturing Base

Sai Parenterals owns and operates five strategically located manufacturing facilities, four in Hyderabad and one in Ongole, with a collective installed capacity of 1,160 million units per year. These facilities hold key accreditations, including TGA-Australia and PIC/S certifications, enabling efficient exports to Regulated Markets. Automation and proximity to major ports ensure logistics optimization and cost-efficient operations.

Extensive Domestic and Global Network

The Company possesses a well-established distribution network, securing a strong presence in Indian institutional markets by participating in government tenders and supplying to PMBJP centers. Internationally, the Company is growing its footprint in Australia, SE Asia, and Africa. This dual strategy leverages a super stockist network domestically and regional distributors abroad, ensuring a broad and reliable market reach.

Seasoned Management and Domain Expertise

Sai Parenterals is led by experienced promoters and a technically skilled senior management team with extensive domain knowledge in pharmaceutical manufacturing, commercial operations, and regulatory compliance. The Managing Director, Anil Kumar Karusala, brings over 31 years of experience, providing strategic direction that has been crucial in driving business expansion, entry into regulated markets, and establishing long-term customer loyalty.

More About Sai Parenteral’s Limited

Sai Parenteral’s Limited is a diversified pharmaceutical company involved in branded generic formulations and Contract Development and Manufacturing Organisation (CDMO) services. The company manufactures and develops pharmaceutical products across various therapeutic areas, such as cardiovascular, neuropsychiatry, anti-diabetic, respiratory health, and dermatology. Sai Parenteral’s portfolio includes injectables, tablets, capsules, oral liquids, and ointments, catering to both domestic and international markets.

Business Operations and Product Offerings

The company’s branded generic formulations are sold to a diverse customer base, including government agencies, hospitals, and pharmaceutical companies in India. Since its export expansion in Fiscal 2023, Sai Parenteral has been exporting products to regulated and semi-regulated markets, including Australia, New Zealand, Southeast Asia, and the Middle East. The company also offers CDMO services, focusing on product development, regulatory filings, and commercial manufacturing. This, combined with their robust R&D capabilities, positions them as a preferred partner in the global pharmaceutical market.

Strategic Acquisitions and Growth

To expand its footprint, Sai Parenteral’s Limited has acquired multiple facilities and made strategic investments. For example, in 2023, the company acquired two internationally accredited manufacturing units in Hyderabad, enhancing its capacity for sterile injectable formulations. Additionally, the proposed acquisition of Noumed Pharmaceuticals in Australia will further strengthen Sai Parenteral’s global presence and CDMO capabilities.

Manufacturing Facilities

Sai Parenteral operates five manufacturing units in India, with a combined installed capacity of 1,160 million units annually. The company is in the process of expanding and upgrading its facilities, with plans to increase capacity and achieve new certifications to meet growing demand for specialized products.

Research & Development

The company’s R&D focus includes developing complex formulations and drug delivery systems, catering to both internal needs and CDMO clients. Equipped with advanced quality control laboratories and skilled personnel, Sai Parenteral ensures its products meet the highest regulatory standards

Industry Outlook

The Indian pharmaceutical industry is one of the fastest-growing sectors in the country and is poised to continue its growth trajectory over the next few years. The sector’s overall outlook remainshighly optimistic, driven by increasing demand both domestically and globally.

Growth Prospects and CAGR

• The Indian pharmaceutical market is expected to grow at a Compound Annual Growth Rate (CAGR) of approximately 11-12% from 2023 to 2030.

• By 2030, the market size is projected to reach over USD 65 billion, making India one of the leading pharmaceutical markets globally.

Growth Drivers

• Increasing healthcare access: Rising government initiatives, growing middle-class income, and improved healthcare access are key drivers.

• R&D and innovation: Companies are focusing on complex formulations and generic drugs, including injectables and biosimilars.

• Regulatory Support: The government’s push for ‘Make in India’ initiatives and favorable regulatory policies further boost the industry’s prospects.

• Global export potential: Indian pharma exports have surged, especially in regulated markets like the US and Europe, and semi-regulated markets in Africa and Asia.

Key Figures and Values

• India accounts for 20% of global generic exports by volume and is the largest supplier of generic drugs globally.

• The Indian pharma sector exports products to more than 200 countries, contributing significantly to the country’s economy.

Product-Specific Outlook
For companies like Sai Parenteral’s Limited, which focus on injectables, branded generic formulations, and CDMO services, the demand for these products is expected to rise, particularly in:

• Injectables: Increased healthcare needs and higher demand for critical care and sterile therapies.

• Branded Generics: As healthcare systems worldwide focus on affordable medicines, India’s branded generics are becoming increasingly popular.

• CDMO services: The rise of global pharmaceutical outsourcing to India will continue to fuel growth in this segment.

How Will Sai Parenteral’s Limited Benefit

• Sai Parenteral’s focus on injectables aligns with the growing demand for critical care and sterile therapies, positioning the company for increased market share in both domestic and international markets.

• The rise in global demand for affordable branded generics offers significant growth opportunities for the company’s product offerings.

• Sai Parenteral’s established expertise in CDMO services is well-timed as more global pharmaceutical companies outsource manufacturing to India.

• The company’s expansion into regulated markets, such as Australia, New Zealand, and Europe, will benefit from India’s surge in pharma exports and its recognition as a global leader in generics.

• The push for R&D and innovation will enhance the company’s ability to introduce new, complex formulations, keeping it competitive and aligned with industry trends.

• Government support for ‘Make in India’ initiatives further strengthens Sai Parenteral’s growth prospects, especially in manufacturing and export expansion.

Peer Group Comparison

Name of Company	Face Value (₹)	Revenue (₹ million)	EPS Basic (₹)	EPS Diluted (₹)	P/E (Times)	RoNW (%)	NAV (₹)
Sai Parenteral’s Limited	5	1,631.06	5.43	5.43	[●]	15.09%	35.98
Peer Group
Sai Life Sciences Limited	1	16,945.70	8.83	8.61	107.99	7.99%	102.12
Innova Captab Limited	10	12,436.76	22.41	22.41	37.47	13.37%	167.66
Senores Pharmaceuticals Limited	10	3,982.50	16.12	16.12	55.08	7.18%	176.37
Gland Pharma Limited	1	56,165.04	42.40	42.40	46.53	7.63%	555.41

Key Strategies for Sai Parenteral’s Limited

Global Injectable Formulations Expansion

Sai Parenteral’s Limited is expanding its presence in Regulated and Semi-Regulated markets for injectables, allocating1107.95$ million for unit upgrades by Fiscal 2027. This investment aims to achieve EU-GMP and PIC/S certifications, enhance capacity to 117 million units, and introduce high-value lyophilised vial and cartridge manufacturing capabilities.

Capitalising on CDMO Opportunities

The company’s strategy is to leverage its manufacturing capabilities and enhanced R&D competences to capitalise on the growing global CDMO market. This involves targeting Regulated and Semi-Regulated markets for injectables and oral solid dosages, supported by facility upgrades, capacity expansion, and the development of a dedicated R&D Centre.

Strengthening Presence via Noumed Acquisition

Sai Parenteral’s is strengthening its CDMO and market reach through the proposed acquisition of a majority stake in Australia’s Noumed Pharmaceuticals. This move grants access to Noumed’s long-term supply agreements, 451 approved dossiers, and an upcoming Australian manufacturing facility, enhancing the company’s competitive edge in regulated markets.

Focus on New Product Development

Sai Parenteral’s plans to drive future growth by dedicating 180.23 million to establish an advanced R&D Centre operated by its subsidiary, SP Analytics. This centre will focus on novel formulations, regulatory dossier submissions, and developing cost-effective generics for patents expiring soon, supporting both in-house and CDMO business needs.

Grow Branded Generic Formulations Business

The company aims to expand its Branded Generic Formulations business across Semi-Regulated Markets like Latin America, Asia, the Middle East, and Africa. Leveraging upcoming certifications (PIC/S, EU-GMP, TGA) and Noumed’s approved dossiers, Sai Parenteral’s will significantly strengthen its export portfolio and grow its market share in the institutional segment